These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25099201)

  • 1. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Watanabe K; Mimura M; Uchida H
    J Clin Psychiatry; 2014 Nov; 75(11):1209-14. PubMed ID: 25099201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.
    Mizuno Y; Bies RR; Remington G; Mamo DC; Suzuki T; Pollock BG; Tsuboi T; Watanabe K; Mimura M; Uchida H
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):182-7. PubMed ID: 22230651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
    Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
    Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
    Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
    J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
    Tsuboi T; Bies RR; Suzuki T; Mamo DC; Pollock BG; Graff-Guerrero A; Mimura M; Uchida H
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():178-82. PubMed ID: 23727135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study.
    Tsuboi T; Suzuki T; Bies RR; Remington G; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2015 May; 164(1-3):149-54. PubMed ID: 25864950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
    Takeuchi H; Suzuki T; Remington G; Bies RR; Abe T; Graff-Guerrero A; Watanabe K; Mimura M; Uchida H
    Schizophr Bull; 2013 Sep; 39(5):993-8. PubMed ID: 23821768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
    Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
    Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
    J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial.
    Ozawa C; Bies RR; Pillai N; Suzuki T; Mimura M; Uchida H
    J Clin Psychopharmacol; 2019; 39(4):329-335. PubMed ID: 31188232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels and estimated dopamine D
    Ikai S; Suzuki T; Mimura M; Uchida H
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):4003-4010. PubMed ID: 27631410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.